
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNCF | OTC Markets | USD | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZN | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Xetra | EUR | Delayed | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed |
AstraZeneca PLC reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported revenue was USD 11,207 million compared to USD 12,011 million a year ago. Net income was USD 901 million compared to net loss of USD 347 million a year ago. Basic earnings per share from continuing operations was USD 0.58 compared to basic loss per share from continuing operations of USD 0.22 a year ago. Diluted earnings per share from continuing operations was USD 0.58 compared to diluted loss per share from continuing operations of USD 0.22 a year ago.
Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
---|---|---|---|---|
Total Revenue | 11207 | 10982 | 10771 | 11390 |
Gross Profit | 8737 | 8941 | 8942 | 9111 |
Operating Income | 1668 | 2282 | 2021 | 2808 |
Net Income | 901 | 1640 | 360 | 386 |
Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
---|---|---|---|---|
Total Assets | 96483 | 94185 | 96579 | 100273 |
Total Liabilities | 59425 | 59031 | 60628 | 63914 |
Total Equity | 37058 | 35154 | 35951 | 36359 |
Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 2398 | 2930 | 1248 | 3232 |
Cash From Investing Activities | -249 | -1743 | -800 | -168 |
Cash From Financing Activities | -358 | -1430 | -1295 | -3740 |
Net Change in Cash | 1797 | -294 | -873 | -685 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review